Latest Conference Coverage
Adding New Mechanistic Agents to SMA Treatment: the Phase 3 RESILIENT Study
May 13th 2024Lindsey Lee Lair, MD, a neurologist and vice president of clinical development at Biohaven Pharmaceuticals, provided insight on an ongoing pivotal trial assessing the impacts of taldefgrobep alfa, a myostatin inhibitor, in patients with SMA.
Understanding the Root of REM Behavior Disorder and Other Parasomnias
May 8th 2024Alberto Ramos, MD, FAAN, director of the Sleep Disorders program at the University of Miami, provided commentary on a session chaired at AAN 2024 assessing the diagnostic criteria and treatment options of parasomnias in adults.
Understanding the Impact of Data Analysis on Preventive Migraine Treatment: Jessica Ailani, MD
May 7th 2024The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]
Understanding the Therapeutic Potential of Nipocalimab: Katie Abouzahr, MD
May 6th 2024The vice president, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson, provided perspective on the unique molecular structure of nipocalimab seen across nonclinical and clinical studies. [WATCH TIME: 3 minutes]
A Call to Action to Address Disparities in Multiple Sclerosis Care: Jaime Imitola, MD
May 6th 2024The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]
Addressing Potential Causes of Burnout Through Productive Solutions: Neil Busis, MD
May 3rd 2024The associate chair for technology and innovation at the NYU Grossman School of Medicine provided commentary on a study from AAN 2024 that examined the driving factors behind burnout in neurology departments. [WATCH TIME: 4 minutes]
Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods
May 2nd 2024Tanisha Hill-Jarrett, PhD, an assistant professor of neurology at the University of California, San Francisco Memory and Aging Center, discussed the change needed to improve cognitive decline rates in Black women in disadvantaged neighborhoods.
Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD
May 2nd 2024The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]
Latest Findings on AXS-05 Treatment for Agitation in Alzheimer Disease: Anton P. Porsteinsson, MD
May 1st 2024The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]
Literature Review Demonstrates Ravulizumab’s Superior Efficacy Over Other Approved NMOSD Treatments
April 29th 2024In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.
Use of Antiemetics in Parkinson Care
April 25th 2024In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.
Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc
April 24th 2024The chair of neurology at Massachusetts General Hospital talked about results from the phase 2b PARADIGM trial assessing PrimeC, an ALS combination agent that consists of ciprofloxacin and celecoxib. [WATCH TIME: 4 minutes]
